# A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis.

> **NCT01863771** · PHASE3 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 144 (actual)

## Conditions studied

- Colitis, Ulcerative

## Interventions

- **DRUG:** Golimumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01863771
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-15
- **Primary completion:** 2016-01-29
- **Final completion:** 2016-01-29
- **Target enrollment:** 144 (ACTUAL)
- **Last updated:** 2017-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01863771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01863771, "A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01863771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*